Discontinued — last reported Q2 '20
Current Liabilities
Lease Liability Payments - Remainder of Fiscal Year
Royalty Pharma Lease Liability Payments - Remainder of Fiscal Year decreased by 6.5% to $3.79M in Q1 2026 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalLower is better
VolatilityStable
First reportedQ4 2019
Last reportedQ2 2020
How to read this metric
Higher values indicate greater near-term cash outflows, impacting short-term liquidity and working capital.
Detailed definition
The total cash outflows required to satisfy operating and finance lease obligations for the remaining portion of the cur...
Peer comparison
Standard disclosure under ASC 842 lease accounting standards.
Metric ID:
lease_liability_payments_remainder_fiscal_yearHistorical Data
3 periods
| Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|
| Value | $4.05M | $4.05M | $3.79M |
| QoQ Change | — | +0.0% | -6.5% |
Range$3.79M – $4.05M
Lease Liability Payments - Remainder of Fiscal Year at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's lease liability payments - remainder of fiscal year?
- Royalty Pharma (RPRX) reported lease liability payments - remainder of fiscal year of $3.79M in Q1 2026.
- What does lease liability payments - remainder of fiscal year mean?
- The amount of lease payments due before the end of the current fiscal year.